Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Human ApoA-I overexpression enhances macrophage-specific reverse cholesterol transport but fails to prevent inherited diabesity in mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Farré, Núria|||0000-0003-3110-6572
  • Santos, David|||0000-0003-1157-4969
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Metso, Jari
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Errico, Teresa Laura
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Human apolipoprotein A-I (hApoA-I) overexpression improves high-density lipoprotein (HDL) function and the metabolic complications of obesity. We used a mouse model of diabesity, the db/db mouse, to examine the effects of hApoA-I on the two main functional properties of HDL, i.e., macrophage-specific reverse cholesterol transport (m-RCT) in vivo and the antioxidant potential, as well as the phenotypic features of obesity. HApoA-I transgenic (hA-I) mice were bred with nonobese control (db/+) mice to generate hApoA-I-overexpressing db/+ offspring, which were subsequently bred to obtain hA-I-db/db mice. Overexpression of hApoA-I significantly increased weight gain and the incidence of fatty liver in db/db mice. Weight gain was mainly explained by the increased caloric intake of hA-I-db/db mice (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness

  • Revilla, Giovanna|||0000-0003-2971-5651
  • Pons, Monica de Pablo
  • Baila-Rueda, Lucía
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Santos, David|||0000-0003-1157-4969
  • Cenarro, Ana
  • Magalhaes, Marcelo
  • Blanco, R. M.
  • Moral, Antonio|||0000-0001-5551-0145
  • Pérez, José Ignacio
  • Sabé, Gerard
  • González, Cintia|||0000-0003-2551-9979
  • Fuste, Victoria|||0000-0001-5065-3737
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Faria, Manuel dos Santos
  • De Leiva Hidalgo, Alberto|||0000-0002-0419-6771
  • Corcoy i Pla, Rosa|||0000-0001-5055-6814
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Mato, Eugènia|||0000-0001-8121-9335
Cholesterol mediates its proliferative and metastatic effects via the metabolite 27-hydroxycholesterol (27-HC), at least in breast and endometrial cancer. We determined the serum lipoprotein profile, intratumoral cholesterol and 27-HC levels in a cohort of patients with well-differentiated papillary thyroid carcinoma (PTC; low/intermediate and high risk), advanced thyroid cancers (poorly differentiated, PDTC and anaplastic thyroid carcinoma, ATC) and benign thyroid tumors, as well as the expression of genes involved in cholesterol metabolism. We investigated the gene expression profile, cellular proliferation, and migration in Nthy-ori 3.1 and CAL-62 cell lines loaded with human low-density lipoprotein (LDL). Patients with more aggressive tumors (high-risk PTC and PDTC/ATC) showed a decrease in blood LDL cholesterol and apolipoprotein B. These changes were associated with an increase in the expression of the thyroid's LDL receptor, whereas 3-hydroxy-3-methylglutaryl-CoA reductase and 25-hydroxycholesterol 7-alpha-hydroxylase were downregulated, with an intratumoral increase of the 27-HC metabolite. Furthermore, LDL promoted proliferation in both the Nthy-ori 3.1 and CAL-62 thyroid cellular models, but only in ATC cells was its cellular migration increased significantly. We conclude that cholesterol and intratumoral accumulation of 27-HC promote the aggressive behavior process of PTC. Targeting cholesterol metabolism could be a new therapeutic strategy in thyroid tumors with poor prognosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunization with the Gly 1127 -Cys 1140 amino acid sequence of the LRP1 receptor reduces atherosclerosis in rabbits. Molecular, immunohistochemical and nuclear imaging studies

  • Bornachea, Olga
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Nasarre, Laura
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Cedó, Lídia|||0000-0003-4354-3411
  • Iborra Obiols, Antoni|||0000-0002-8984-5151
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Juárez Rubio, Cándido|||0000-0003-2235-9893
  • Cámara, Juan Antonio|||0000-0001-7494-1127
  • Espinet, Carina|||0000-0001-8580-6617
  • Borrell-Pages, Maria|||0000-0002-1759-9756
  • Badimon, Lina|||0000-0002-9162-2459
  • Castell-Conesa, Joan|||0000-0002-6449-9731
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background : The LRP1 (CR9) domain and, in particular, the sequence Gly 1127 -Cys 1140 (P3) plays a critical role in the binding and internalization of aggregated LDL (agLDL). We aimed to evaluate whether immunization with P3 reduces high-fat diet (HFD)-induced atherosclerosis. Methods : Female New Zealand White (NZW) rabbits were immunized with a primary injection and four reminder doses (R1-R4) of IrP (irrelevant peptide) or P3 conjugated to the carrier. IrP and P3-immunized rabbits were randomly divided into a normal diet group and a HFD-fed group. Anti-P3 antibody levels were determined by ELISA. Lipoprotein profile, circulating and tissue lipids, and vascular pro-inflammatory mediators were determined using standardized methods while atherosclerosis was determined by confocal microscopy studies and non-invasive imaging (PET/CT and Doppler ultrasonography). Studies treating human macrophages (hMΦ) and coronary vascular smooth muscle cells (hcVSMC) with rabbit serums were performed to ascertain the potential impact of anti-P3 Abs on the functionality of these crucial cells. Results : P3 immunization specifically induced the production of anti-P3 antibodies (Abs) and did not alter the lipoprotein profile. HFD strongly induced cholesteryl ester (CE) accumulation in the aorta of both the control and IrP groups, and their serum dose-dependently raised the intracellular CE of hMΦ and hcVSMC, promoting TNFR1 and phospho-NF-kB (p65) overexpression. These HFD pro-inflammatory effects were dramatically decreased in the aorta of P3-immunized rabbits and in hMΦ and hcVSMC exposed to the P3 rabbit serums. Microscopy studies revealed that P3 immunization reduced the percentage of lipids, macrophages, and SMCs in the arterial intima, as well as the atherosclerotic extent and lesion area in the aorta. PET/CT and Doppler ultrasonography studies showed that the average standardized uptake value (SUV) of the aorta and the arterial resistance index (ARI) of the carotids were more upregulated by HFD in the control and IrP groups than the P3 group. Conclusions : P3 immunization counteracts HFD-induced fatty streak formation in rabbits. The specific blockade of the LRP1 (CR9) domain with Anti-P3 Abs dramatically reduces HFD-induced intracellular CE loading and harmful coupling to pro-inflammatory signaling in the vasculature.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effects of virgin olive oil and phenol-enriched virgin olive oils on lipoprotein atherogenicity

  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Canyelles, Marina|||0000-0002-0278-5337
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
The atherogenicity of low-density lipoprotein (LDL) and triglyceride-rich lipoproteins (TRLs) may be more significant than LDL cholesterol levels. Clinical trials which have led to increased high-density lipoprotein (HDL) cholesterol have not always seen reductions in cardiovascular disease (CVD). Furthermore, genetic variants predisposing individuals to high HDL cholesterol are not associated with a lower risk of suffering a coronary event, and therefore HDL functionality is considered to be the most relevant aspect. Virgin olive oil (VOO) is thought to play a protective role against CVD. This review describes the effects of VOO and phenol-enriched VOOs on lipoprotein atherogenicity and HDL atheroprotective properties. The studies have demonstrated a decrease in LDL atherogenicity and an increase in the HDL-mediated macrophage cholesterol efflux capacity, HDL antioxidant activity, and HDL anti-inflammatory characteristics after various VOO interventions. Moreover, the expression of cholesterol efflux-related genes was enhanced after exposure to phenol-enriched VOOs in both post-prandial and sustained trials. Improvements in HDL antioxidant properties were also observed after VOO and phenol-enriched VOO interventions. Furthermore, some studies have demonstrated improved characteristics of TRL atherogenicity under postprandial conditions after VOO intake. Large-scale, long-term randomized clinical trials, and Mendelian analyses which assess the lipoprotein state and properties, are required to confirm these results.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Macrophage Cholesterol Efflux Downregulation Is Not Associated with Abdominal Aortic Aneurysm (AAA) Progression

  • Canyelles, Marina|||0000-0002-0278-5337
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Lindholt, Jes S.|||0000-0001-9536-4488
  • Santos, David|||0000-0003-1157-4969
  • Fernández, Irati|||0000-0002-4607-9821
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Martín-Ventura, José Luís|||0000-0002-5972-8712
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Recent studies have raised the possibility of a role for lipoproteins, including high-density lipoprotein cholesterol (HDLc), in abdominal aortic aneurysm (AAA). The study was conducted in plasmas from 39 large size AAA patients (aortic diameter.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide -[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Rull, Anna|||0000-0002-8907-7754
  • Aldana-Ramos, Joile
  • Santos, David|||0000-0003-1157-4969
  • Puig, Nuria
  • Farre-Cabrerizo, Nuria
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pérez, Antonio|||0000-0001-5528-1143
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Mimetic peptides are potential therapeutic agents for atherosclerosis. -[113-122]apolipoprotein (apo) J (-[113-122]apoJ) is a 10-residue peptide that is predicted to form a class G* amphipathic helix 6 from apoJ; it shows anti-inflammatory and anti-atherogenic properties. In the present study, we analyzed the effect of -[113-122]apoJ in low-density lipoprotein receptor knockout mice(LDLR-KO) on the development of atherosclerosis and lipoprotein function. Fifteen-week-old female LDLR-KO mice fed an atherogenic Western-type diet were treated for eight weeks with -[113-122]apoJ peptide, a scrambled peptide, or vehicle. Peptides were administered subcutaneously three days per week (200 µg in 100 µL of saline). After euthanasia, blood and hearts were collected and the aortic arch was analyzed for the presence of atherosclerotic lesions. Lipoproteins were isolated and their composition and functionality were studied. The extent of atherosclerotic lesions was 43% lower with -[113-122]apoJ treatment than with the vehicle or scramble. The lipid profile was similar between groups, but the high-density lipoprotein (HDL) of -[113-122]apoJ-treated mice had a higher antioxidant capacity and increased ability to promote cholesterol efflux than the control group. In addition, low-density lipoprotein (LDL) from -[113-122]apoJ-treated mice was more resistant to induced aggregation and presented lower electronegativity than in mice treated with -[113-122]apoJ. Our results demonstrate that the -[113-122]apoJ peptide prevents the extent of atherosclerotic lesions, which could be partially explained by the improvement of lipoprotein functionality.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Phenol-Enriched Virgin Olive Oil Promotes Macrophage-Specific Reverse Cholesterol Transport In Vivo

  • Cedó, Lídia|||0000-0003-4354-3411
  • Fernández-Castillejo, Sara|||0000-0002-8109-9713
  • Rubió, Laura
  • Metso, Jari
  • Santos, David|||0000-0003-1157-4969
  • Muñoz Aguayo, Daniel|||0000-0001-8173-0168
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Motilva, Maria-José|||0000-0001-8985-7737
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Solà, Rosa|||0000-0002-8359-235X
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
The intake of olive oil (OO) enriched with phenolic compounds (PCs) promotes ex vivo HDL-mediated macrophage cholesterol efflux in humans. We aimed to determine the effects of PC-enriched virgin OO on reverse cholesterol transport (RevCT) from macrophages to feces in vivo. Female C57BL/6 mice were given intragastric doses of refined OO (ROO) and a functional unrefined virgin OO enriched with its own PC (FVOO) for 14 days. Our experiments included two independent groups of mice that received intragastric doses of the phenolic extract (PE) used to prepare the FVOO and the vehicle solution (saline), as control, for 14 days. FVOO intake led to a significant increase in serum HDL cholesterol and its ability to induce macrophage cholesterol efflux in vitro when compared with ROO group. This was concomitant with the enhanced macrophage-derived [ 3 H]cholesterol transport to feces in vivo. PE intake per se also increased HDL cholesterol levels and significantly promoted in vivo macrophage-to-feces RevCT rate when compared with saline group. PE upregulated the expression of the main macrophage transporter involved in macrophage cholesterol efflux, the ATP binding cassette a1. Our data provide direct evidence of the crucial role of OO PCs in the induction of macrophage-specific RevCT in vivo.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Cross-Talk between Inflammatory Mediators and the Epithelial Mesenchymal Transition Process in the Development of Thyroid Carcinoma

  • Revilla, Giovanna|||0000-0003-2971-5651
  • Corcoy i Pla, Rosa|||0000-0001-5055-6814
  • Moral, Antonio|||0000-0001-5551-0145
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Mato, Eugènia|||0000-0001-8121-9335
There is strong association between inflammatory processes and their main metabolic mediators, such as leptin, adiponectin secretion, and low/high-density lipoproteins, with the cancer risk and aggressive behavior of solid tumors. In this scenario, cancer cells (CCs) and cancer stem cells (CSCs) have important roles. These cellular populations, which come from differentiated cells and progenitor stem cells, have increased metabolic requirements when it comes to maintaining or expanding the tumors, and they serve as links to some inflammatory mediators. Although the molecular mechanisms that are involved in these associations remain unclear, the two following cellular pathways have been suggested: 1) the mesenchymal-epithelial transition (MET) process, which permits the differentiation of adult stem cells throughout the acquisition of cell polarity and the adhesion to epithelia, as well to new cellular lineages (CSCs); and, 2) a reverse process, termed the epithelial-mesenchymal transition (EMT), where, in pathophysiological conditions (tissue injury, inflammatory process, and oxidative stress), the differentiated cells can acquire a multipotent stem cell-like phenotype. The molecular mechanisms that regulate both EMT and MET are complex and poorly understood. Especially, in the thyroid gland, little is known regarding MET/EMT and the role of CCs or CSCs, providing an exciting, new area of knowledge to be investigated. This article reviews the progress to date in research on the role of inflammatory mediators and metabolic reprogramming during the carcinogenesis process of the thyroid gland and the EMT pathways.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

HDL and LDL, Potential New Players in Breast Cancer Development

  • Cedó, Lídia|||0000-0003-4354-3411
  • Reddy, Srinivasa T.
  • Mato, Eugènia|||0000-0001-8121-9335
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
Breast cancer is the most prevalent cancer and primary cause of cancer-related mortality in women. The identification of risk factors can improve prevention of cancer, and obesity and hypercholesterolemia represent potentially modifiable breast cancer risk factors. In the present work, we review the progress to date in research on the potential role of the main cholesterol transporters, low-density and high-density lipoproteins (LDL and HDL), on breast cancer development. Although some studies have failed to find associations between lipoproteins and breast cancer, some large clinical studies have demonstrated a direct association between LDL cholesterol levels and breast cancer risk and an inverse association between HDL cholesterol and breast cancer risk. Research in breast cancer cells and experimental mouse models of breast cancer have demonstrated an important role for cholesterol and its transporters in breast cancer development. Instead of cholesterol, the cholesterol metabolite 27-hydroxycholesterol induces the proliferation of estrogen receptor-positive breast cancer cells and facilitates metastasis. Oxidative modification of the lipoproteins and HDL glycation activate different inflammation-related pathways, thereby enhancing cell proliferation and migration and inhibiting apoptosis. Cholesterol-lowering drugs and apolipoprotein A-I mimetics have emerged as potential therapeutic agents to prevent the deleterious effects of high cholesterol in breast cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Administration of CORM-2 inhibits diabetic neuropathy but does not reduce dyslipidemia in diabetic mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Santos, David|||0000-0003-1157-4969
  • Farré, Núria|||0000-0003-3110-6572
  • Ruiz-Nogales, Sheila
  • Leánez, Sergi
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Zapico Muñiz, Edgar|||0000-0002-8921-1167
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Pol, Olga|||0000-0002-4621-8457
The antinociceptive effects of the carbon monoxide-releasing molecule tricarbonyldichlororuthenium (II) dimer (CORM-2) during chronic pain are well documented, but most of its possible side-effects remain poorly understood. In this work, we examine the impact of CORM-2 treatment on the lipoprotein profile and two main atheroprotective functions attributed to high-density lipoprotein (HDL) in a mouse model of type 1 diabetes while analyzing the effect of this drug on diabetic neuropathy. Streptozotocin (Stz)-induced diabetic mice treated with CORM-2 (Stz-CORM-2) or vehicle (Stz-vehicle) were used to evaluate the effect of this drug on the modulation of painful diabetic neuropathy using nociceptive behavioral tests. Plasma and tissue samples were used for chemical and functional analyses, as appropriate. Two main antiatherogenic properties of HDL, i.e., the ability of HDL to protect low-density lipoprotein (LDL) from oxidation and to promote reverse cholesterol transport from macrophages to the liver and feces in vivo (m-RCT), were also assessed. Stz-induced diabetic mice displayed hyperglycemia, dyslipidemia and pain hypersensitivity. The administration of 10 mg/kg CORM-2 during five consecutive days inhibited allodynia and hyperalgesia and significantly ameliorated spinal cord markers (Cybb and Bdkrb1 expression) of neuropathic pain in Stz mice, but it did not reduce the combined dyslipidemia shown in Stz-treated mice. Its administration to Stz-treated mice led to a significant increase in the plasma levels of cholesterol (∼ 1.4-fold vs. Ctrl, ∼ 1.3- fold vs. Stz-vehicle; p < 0.05) and was attributed to significant elevations in both non-HDL (∼ 1.8-fold vs. Ctrl; ∼ 1.6-fold vs. Stz-vehicle; p < 0.05) and HDL cholesterol (∼ 1.3-fold vs. Ctrl, ∼ 1.2-fold vs. Stz-vehicle; p < 0.05). The increased HDL in plasma was not accompanied by a commensurate elevation in m-RCT in Stz-CORM-2 compared to Stz-vehicle mice; instead, it was worsened as revealed by decreased [ 3 H]-tracer trafficking into the feces in vivo. Furthermore, the HDL-mediated protection against LDL oxidation ex vivo shown by the HDL isolated from Stz-CORM-2 mice did not differ from that obtained in Stz-vehicle mice. In conclusion, the antinociceptive effects produced by a high dose of CORM-2 were accompanied by antioxidative effects but were without favorable effects on the dyslipidemia manifested in diabetic mice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Trimethylamine N -Oxide, A Link among Diet, Gut Microbiota, Gene Regulation of Liver and Intestine Cholesterol Homeostasis and HDL Function

  • Canyelles, Marina|||0000-0002-0278-5337
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Cedó, Lídia|||0000-0003-4354-3411
  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Recent evidence, including massive gene-expression analysis and a wide-variety of other multi-omics approaches, demonstrates an interplay between gut microbiota and the regulation of plasma lipids. Gut microbial metabolism of choline and -carnitine results in the formation of trimethylamine (TMA) and concomitant conversion into trimethylamine- N -oxide (TMAO) by liver flavin monooxygenase 3 (FMO3). The plasma level of TMAO is determined by the genetic variation, diet and composition of gut microbiota. Multiple studies have demonstrated an association between TMAO plasma levels and the risk of atherothrombotic cardiovascular disease (CVD). We aimed to review the molecular pathways by which TMAO production and FMO3 exert their proatherogenic effects. TMAO may promote foam cell formation by upregulating macrophage scavenger receptors, deregulating enterohepatic cholesterol and bile acid metabolism and impairing macrophage reverse cholesterol transport (RCT). Furthermore, FMO3 may promote dyslipidemia by regulating multiple genes involved in hepatic lipogenesis and gluconeogenesis. FMO3 also impairs multiple aspects of cholesterol homeostasis, including transintestinal cholesterol export and macrophage-specific RCT. At least part of these FMO3-mediated effects on lipid metabolism and atherogenesis seem to be independent of the TMA/TMAO formation. Overall, these findings have the potential to open a new era for the therapeutic manipulation of the gut microbiota to improve CVD risk.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Human hepatic lipase overexpression in mice induces hepatic steatosis and obesity through promoting hepatic lipogenesis and white adipose tissue lipolysis and fatty acid uptake

  • Cedó, Lídia|||0000-0003-4354-3411
  • Santos, David|||0000-0003-1157-4969
  • Roglans, Núria
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Pallarès, Victor|||0000-0002-9851-0345
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
Human hepatic lipase (hHL) is mainly localized on the hepatocyte cell surface where it hydrolyzes lipids from remnant lipoproteins and high density lipoproteins and promotes their hepatic selective uptake. Furthermore, hepatic lipase (HL) is closely associated with obesity in multiple studies. Therefore, HL may play a key role on lipid homeostasis in liver and white adipose tissue (WAT). In the present study, we aimed to evaluate the effects of hHL expression on hepatic and white adipose triglyceride metabolism in vivo. Experiments were carried out in hHL transgenic and wild-type mice fed a Western-type diet. Triglyceride metabolism studies included β-oxidation and de novo lipogenesis in liver and WAT, hepatic triglyceride secretion, and adipose lipoprotein lipase (LPL)-mediated free fatty acid (FFA) lipolysis and influx. The expression of hHL promoted hepatic triglyceride accumulation and de novo lipogenesis without affecting triglyceride secretion, and this was associated with an upregulation of Srebf1 as well as the main genes controlling the synthesis of fatty acids. Transgenic mice also exhibited more adiposity and an increased LPL-mediated FFA influx into the WAT without affecting glucose tolerance. Our results demonstrate that hHL promoted hepatic steatosis in mice mainly by upregulating de novo lipogenesis. HL also upregulated WAT LPL and promoted triglyceride-rich lipoprotein hydrolysis and adipose FFA uptake. These data support the important role of hHL in regulating hepatic lipid homeostasis and confirm the broad cardiometabolic role of HL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impaired HDL (high-density lipoprotein)-mediated macrophage cholesterol efflux in patients with abdominal aortic aneurysm-brief report

  • Martínez-López, Diego
  • Cedó, Lídia|||0000-0003-4354-3411
  • Metso, Jari
  • Burillo, Elena
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Canyelles, Marina|||0000-0002-0278-5337
  • Lindholt, Jes S.|||0000-0001-9536-4488
  • Torres-Fonseca, Monica
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Martín-Ventura, Jose Luis
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
Objective-The ability of HDL (high-density lipoprotein) to promote macrophage cholesterol efflux is considered the main HDL cardioprotective function. Abdominal aortic aneurysm (AAA) is usually characterized by cholesterol accumulation and macrophage infiltration in the aortic wall. Here, we aim to evaluate the composition of circulating HDL particles and their potential for promoting macrophage cholesterol efflux in AAA subjects. Approach and Results-First, we randomly selected AAA and control subjects from Spain. The AAA patients in the Spanish cohort showed lower plasma apoA-I levels concomitantly associated with low levels of plasma HDL cholesterol and the amount of preβ-HDL particles. We determined macrophage cholesterol efflux to apoB-depleted plasma, which contains mature HDL, preβ-HDL particles and HDL regulatory proteins. ApoB-depleted plasma from AAA patients displayed an impaired ability to promote macrophage cholesterol efflux. Next, we replicated the experiments with AAA and control subjects derived from Danish cohort. Danish AAA patients also showed lower apoA-I levels and a defective HDL-mediated macrophage cholesterol efflux. Conclusions-AAA patients show impaired HDL-facilitated cholesterol removal from macrophages, which could be mechanistically linked to AAA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Low-density lipoprotein receptor-related protein 1 deficiency in cardiomyocytes reduces susceptibility to insulin resistance and obesity

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Bornachea, Olga
  • Cedó, Lídia|||0000-0003-4354-3411
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Herrero, Laura|||0000-0003-4244-4673
  • Roglans, Nuria
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Nasarre, Laura
  • Camino-López, Sandra|||0000-0002-2737-4892
  • García, Eduardo
  • Mato, Eugènia|||0000-0001-8121-9335
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sebastian, David
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Serra, Dolors|||0000-0002-4936-4206
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background: Low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in fatty acid metabolism and glucose homeostasis. In the context of dyslipemia, LRP1 is upregulated in the heart. Our aim was to evaluate the impact of cardiomyocyte LRP1 deficiency on high fat diet (HFD)-induced cardiac and metabolic alterations, and to explore the potential mechanisms involved. Methods: We used TnT-iCre transgenic mice with thoroughly tested suitability to delete genes exclusively in cardiomyocytes to generate an experimental mouse model with conditional Lrp1 deficiency in cardiomyocytes (TNT-iCre+-LRP1flox/flox). Findings: Mice with Lrp1-deficient cardiomyocytes (cm-Lrp1-/-) have a normal cardiac function combined with a favorable metabolic phenotype against HFD-induced glucose intolerance and obesity. Glucose intolerance protection was linked to higher hepatic fatty acid oxidation (FAO), lower liver steatosis and increased whole-body energy expenditure. Proteomic studies of the heart revealed decreased levels of cardiac pro-atrial natriuretic peptide (pro-ANP), which was parallel to higher ANP circulating levels. cm-Lrp1-/- mice showed ANP signalingactivation that was linked to increased fatty acid (FA) uptake and increased AMPK/ ACC phosphorylation in the liver. Natriuretic peptide receptor A (NPR-A) antagonist completely abolished ANP signaling and metabolic protection in cm-Lrp1-/- mice. Conclusions: These results indicate that an ANP-dependent axis controlled by cardiac LRP1 levels modulates AMPK activity in the liver, energy homeostasis and whole-body metabolism.